^
Association details:
Biomarker:CD8 expression
Cancer:Renal Cell Carcinoma
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Integrative genomic profiling of RCC treated with second-line nivolumab.

Published date:
02/14/2020
Excerpt:
Integrative genomic sequencing analysis of ccRCC tumors in Nivolumab treated patients revealed CD8 expression as a putative biomarker.